BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30667555)

  • 1. Melorheostotic Bone Lesions Caused by Somatic Mutations in MAP2K1 Have Deteriorated Microarchitecture and Periosteal Reaction.
    Fratzl-Zelman N; Roschger P; Kang H; Jha S; Roschger A; Blouin S; Deng Z; Cabral WA; Ivovic A; Katz J; Siegel RM; Klaushofer K; Fratzl P; Bhattacharyya T; Marini JC
    J Bone Miner Res; 2019 May; 34(5):883-895. PubMed ID: 30667555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations.
    Jha S; Fratzl-Zelman N; Roschger P; Papadakis GZ; Cowen EW; Kang H; Lehky TJ; Alter K; Deng Z; Ivovic A; Flynn L; Reynolds JC; Dasgupta A; Miettinen M; Lange E; Katz J; Klaushofer K; Marini JC; Siegel RM; Bhattacharyya T
    J Bone Miner Res; 2019 Jan; 34(1):145-156. PubMed ID: 30138550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case.
    Han X; Xu Y; Wei Z; Wang C; Yue H; Zhang Z
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2043. PubMed ID: 36004822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic activating mutations in MAP2K1 cause melorheostosis.
    Kang H; Jha S; Deng Z; Fratzl-Zelman N; Cabral WA; Ivovic A; Meylan F; Hanson EP; Lange E; Katz J; Roschger P; Klaushofer K; Cowen EW; Siegel RM; Marini JC; Bhattacharyya T
    Nat Commun; 2018 Apr; 9(1):1390. PubMed ID: 29643386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway.
    Kang H; Jha S; Ivovic A; Fratzl-Zelman N; Deng Z; Mitra A; Cabral WA; Hanson EP; Lange E; Cowen EW; Katz J; Roschger P; Klaushofer K; Dale RK; Siegel RM; Bhattacharyya T; Marini JC
    J Exp Med; 2020 May; 217(5):. PubMed ID: 32232430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis.
    Wordsworth P; Chan M
    Calcif Tissue Int; 2019 May; 104(5):530-543. PubMed ID: 30989250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis.
    Allbritton-King JD; Maity J; Patel A; Colbert RA; Navid F; Bhattacharyya T
    J Bone Miner Res; 2023 Dec; 38(12):1834-1845. PubMed ID: 37737377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced cortical porosity and sex-specific patterns of increased bone and osteocyte lacunar mineralization characterize the human distal fibula with aging.
    Hering RN; von Kroge S; Delsmann J; Simon A; Ondruschka B; Püschel K; Schmidt FN; Rolvien T
    Bone; 2024 May; 182():117068. PubMed ID: 38458304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis.
    De Ridder R; Boudin E; Zillikens MC; Ibrahim J; van der Eerden BCJ; Van Hul W; Mortier G
    Bone; 2020 Aug; 137():115406. PubMed ID: 32387835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melorheostosis: A Clinical, Pathologic, and Radiologic Case Series.
    Fick CN; Fratzl-Zelman N; Roschger P; Klaushofer K; Jha S; Marini JC; Bhattacharyya T
    Am J Surg Pathol; 2019 Nov; 43(11):1554-1559. PubMed ID: 31386640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization.
    Fowlkes JL; Bunn RC; Ray PD; Kalaitzoglou E; Uppuganti S; Unal M; Nyman JS; Thrailkill KM
    Bone; 2020 Jan; 130():115106. PubMed ID: 31689526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case Series.
    Gnoli M; Staals EL; Campanacci L; Bedeschi MF; Faletra F; Gallone S; Gaudio A; Mattina T; Gurrieri F; Percesepe A; Neri I; Virdi A; Tremosini M; Milanesi A; Brizola E; Pedrini E; Sangiorgi L
    Calcif Tissue Int; 2019 Aug; 105(2):215-221. PubMed ID: 31129707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Features of Unaffected Skeletal Sites in Melorheostosis: A Case Report.
    Indirli R; Messina C; Longhi M; Guabello G; Corbetta S
    J Clin Densitom; 2020; 23(4):690-694. PubMed ID: 32057643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis.
    Jha S; Ivovic A; Kang H; Meylan F; Hanson EP; Rimland C; Lange E; Katz J; McBride A; Warner AC; Edmondson EF; Cowen EW; Marini JC; Siegel RM; Bhattacharyya T
    J Invest Dermatol; 2021 Mar; 141(3):688-692.e11. PubMed ID: 32791068
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
    Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F
    J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteocyte lacunae in transiliac bone biopsy samples across life span.
    Blouin S; Misof BM; Mähr M; Fratzl-Zelman N; Roschger P; Lueger S; Messmer P; Keplinger P; Rauch F; Glorieux FH; Berzlanovich A; Gruber GM; Brugger PC; Shane E; Recker RR; Zwerina J; Hartmann MA
    Acta Biomater; 2023 Feb; 157():275-287. PubMed ID: 36549635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT analysis of anatomical distribution of melorheostosis challenges the sclerotome hypothesis.
    Jha S; Laucis N; Kim L; Malayeri A; Dasgupta A; Papadakis GZ; Karantanas A; Torres M; Bhattacharyya T
    Bone; 2018 Dec; 117():31-36. PubMed ID: 30218789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melorheostosis: a Rare Sclerosing Bone Dysplasia.
    Kotwal A; Clarke BL
    Curr Osteoporos Rep; 2017 Aug; 15(4):335-342. PubMed ID: 28676968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of estrogen deficiency on cortical bone microporosity and mineralization.
    Sharma D; Larriera AI; Palacio-Mancheno PE; Gatti V; Fritton JC; Bromage TG; Cardoso L; Doty SB; Fritton SP
    Bone; 2018 May; 110():1-10. PubMed ID: 29357314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.